NHS patients are refused "too expensive" prostate cancer drug good enough for Lockerbie terrorist al-Megrahi

NHS patients are refused 'too expensive' prostate cancer drug good enough for Lockerbie terrorist al-Megrahi Cabazitaxel, marketed as Jevtana, can extend the life of late-stage patients by average of three monthsAt 22k per patient deemed 'too expensive' for NHS Abdelbaset Ali al-Megrahi, 60, takes the drug and has survived for three years since his release from prison | UPDATED: 08:14 GMT, 11 May 2012 A life-extending drug hailed as a breakthrough for prostate cancer sufferers and used to treat Lockerbie bomber Abdelbaset Ali al-Megrahi is 'too expensive' to be taken on the NHS.